Digest Network Come funziona
Network
/
Società
Ju
Non verificato

Junshi Biosciences

Di cosa scriviamo

Annunci EconomiciBiotecnologiaManagement/Organizzazione AziendaleMedicina Salute Benessere

25 comunicati stampa

Guarda tutti i comunicati
26/08/2026
Biotecnologia
Management/Organizzazione Aziendale
Junshi Biosciences Announces 2026 Interim Financial Results and Provides Corporate Updates
Fonte
Junshi Biosciences
Emittente
GLOBENEWSWIRE
1.00
0
21/07/2026
Biotecnologia
Medicina Salute Benessere
Junshi Biosciences Announces Acceptance of the Supplemental Application for Toripalimab plus Chemotherapy as Perioperative Treatment for Resectable Stage Ⅱ-Ⅲ NSCLC
Fonte
Junshi Biosciences
Emittente
GLOBENEWSWIRE
1.00
0
01/07/2026
Biotecnologia
Junshi Biosciences Enters Licensing Collaboration with Fosun Wanbang on Roconkibart (IL-17A)
Fonte
Junshi Biosciences
Emittente
GLOBENEWSWIRE
1.00
0
26/05/2026
Biotecnologia
Medicina Salute Benessere
Junshi Biosciences Announces Primary Endpoints Met in Final Analysis of Phase 3 Study for Perioperative Toripalimab plus Chemotherapy for Resectable Stage II-III NSCLC
Fonte
Junshi Biosciences
Emittente
GLOBENEWSWIRE
1.00
0
21/05/2026
Biotecnologia
Medicina Salute Benessere
Annunci Economici
Junshi Biosciences Announces Approval of Toripalimab NDA for the 1st-line treatment of HER2 Expressing Urothelial Carcinoma
Fonte
Junshi Biosciences
Emittente
GLOBENEWSWIRE
1.00
0
20/04/2026
Biotecnologia
Medicina Salute Benessere
Junshi Biosciences Presents Results from JS207 (PD-1/VEGF BsAb) Phase 2 Combo Studies and JS212 (EGFR/HER3 ADC) FIH Phase 1/2 Study at AACR 2026
Fonte
Junshi Biosciences
Emittente
GLOBENEWSWIRE
1.00
0
13/03/2026
Biotecnologia
Management/Organizzazione Aziendale
Junshi Biosciences Announces 2025 Full Year Financial Results and Provides Corporate Updates
Fonte
Junshi Biosciences
Emittente
GLOBENEWSWIRE
1.00
0
09/03/2026
Biotecnologia
Annunci Economici
Junshi Biosciences Announces NMPA Acceptance of New Drug Applications for Toripalimab Injection (Subcutaneous) Across 12 Indications
Fonte
Junshi Biosciences
Emittente
GLOBENEWSWIRE
1.00
0
24/02/2026
Biotecnologia
Management/Organizzazione Aziendale
Medicina Salute Benessere
Junshi Biosciences Announces Strategic Collaboration with Antengene to Evaluate Combination Therapy with JS207 (PD-1/VEGF BsAb) and ATG-037 (Oral CD73 Inhibitor)
Fonte
Junshi Biosciences
Emittente
GLOBENEWSWIRE
1.00
0
05/12/2025
Biotecnologia
Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients
Fonte
Junshi Biosciences
Emittente
GLOBENEWSWIRE
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0